Phase 3 Tecentriq study misses primary endpoint

A Phase 3 study of the checkpoint antibody Tecentriq (atezolizumab) did not meet its primary endpoint of disease-free survival compared with observation in patients with muscle-invasive urothelial cancer, the developer Roche announced on 24 January.